Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes.

"Duality of Interest. R.A. has received advisory fees from Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly and Company, HTL-STREFA, Gilead Sciences, Merck, and Xeris Pharmaceuticals, Inc. and research funding from Novo Nordisk, AstraZeneca, Eli Lilly and Company, Zealand Pharma, Xeris Pharmaceuticals, Inc., Medpace, Kowa Pharmaceuticals, Insulet, Dexcom, and Bayer. M.C.R. has served in an advisory role for Xeris Pharmaceuticals, Inc., Zealand Pharma, Zucara Therapeutics, and Supersapiens; has received compensation as a speaker at scientific sessions, workshops, or both sponsored by Novo Nordisk, Eli Lilly and Company, Sanofi, Insulet, and Medtronic Diabetes; has received in-kind research support from Dexcom; and owns stock and shares with Supersapiens and Zucara Therapeutics. V.C. and M.K.J. are employees of Xeris Pharmaceuticals, Inc. No other potential conflicts of interest relevant to this article were reported."

"Funding. This study was funded by Xeris Pharmaceuticals, Inc."